MedTrace Logo

A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16

NCT03338556 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2018-11-09

Study results available
· View outcomes & findings →

Summary

A study to examine the duration of effect of PrEP-001 in healthy subjects challenged with HRV-16

Conditions

  • Viral Upper Respiratory Tract Infection

Interventions

DRUG

PrEP-001

OTHER

Placebo

Sponsors & Collaborators

  • Hvivo

    collaborator INDUSTRY

  • Prep Biopharm Limited

    lead INDUSTRY

Principal Investigators

  • Cyrus Ghobadi, MD · hVIVO Services Limited

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-06
Primary Completion
2016-09-30
Completion
2016-09-30
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03338556 on ClinicalTrials.gov